Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

927
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
927
Cancer Therapies02:49

Cancer Therapies

8.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.5K
Cancer Therapies02:49

Cancer Therapies

2.4K
2.4K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

820
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
820
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Impact of the Geriatric Nutritional Risk Index on Chemotherapy-Related Adverse Events in Diffuse Large B-Cell Lymphoma: A Multicenter Study.

Nutrients·2025
Same author

Age interaction in associations between geriatric nutritional risk index and prognosis in diffuse large B-cell lymphoma.

Annals of hematology·2025
Same author

Spontaneous Rupture of Solid Pseudopapillary Neoplasm of the Pancreas: A Case Report and Literature Review.

Surgical case reports·2025
Same author

Non-linear relationship between soluble interleukin-2 receptor and prognosis of diffuse large B-cell lymphoma.

Annals of hematology·2024
Same author

Prospective therapeutic studies of disseminated extranodal large B-cell lymphoma including intravascular large B-cell lymphoma.

Global health & medicine·2024
Same author

Neural inference at the frontier of energy, space, and time.

Science (New York, N.Y.)·2023
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

Related Experiment Video

Updated: May 1, 2026

Electrochemotherapy of Tumours
03:57

Electrochemotherapy of Tumours

Published on: December 15, 2008

28.5K

[Chemotherapy].

Shinji Kishi, Takanori Ueda

    Nihon Rinsho. Japanese Journal of Clinical Medicine
    |April 15, 2014
    PubMed
    Summary
    This summary is machine-generated.

    Understanding anticancer drug pharmacology is crucial for safe and effective chemotherapy in malignant lymphoma patients. This chapter reviews drug actions, pharmacokinetics, and pharmacodynamics, highlighting the importance of personalized treatment due to interpatient variability.

    More Related Videos

    Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
    04:48

    Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

    Published on: January 7, 2015

    6.9K
    Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
    05:56

    Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

    Published on: June 21, 2024

    2.8K

    Related Experiment Videos

    Last Updated: May 1, 2026

    Electrochemotherapy of Tumours
    03:57

    Electrochemotherapy of Tumours

    Published on: December 15, 2008

    28.5K
    Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
    04:48

    Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

    Published on: January 7, 2015

    6.9K
    Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
    05:56

    Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

    Published on: June 21, 2024

    2.8K

    Area of Science:

    • Pharmacology
    • Oncology
    • Hematology

    Context:

    • Cancer chemotherapy has improved cure rates for hematological malignancies, including malignant lymphoma.
    • Anticancer drugs often have a narrow therapeutic index, making interpatient variability a significant concern.
    • Understanding drug disposition is critical for safe and effective chemotherapy.

    Purpose:

    • To provide an overview of the pharmacological functions of anticancer agents used in malignant lymphoma.
    • To emphasize the importance of understanding mechanism of action, pharmacokinetics, and pharmacodynamics for safe chemotherapy administration.

    Summary:

    • Chemotherapy advancements have significantly improved outcomes for hematological malignancies.
    • Interpatient variability in drug disposition can impact efficacy and toxicity, especially with narrow therapeutic index drugs.
    • This chapter focuses on the pharmacological aspects of anticancer drugs relevant to malignant lymphoma treatment.

    Impact:

    • Ensures safer and more effective chemotherapy regimens for malignant lymphoma patients.
    • Highlights the need for personalized approaches in cancer treatment based on drug pharmacology.
    • Contributes to improved understanding and management of hematological malignancies through detailed pharmacological insights.